Kyle M. Kremiller
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Kyle M. Kremiller has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Andrew P. Riley
University of Illinois Chicago
1 shared publication - Calvin Johnson
University of Massachusetts Chan Medical School 3 Division of Hematology-Oncology, Department of Medicine Worcester, Massachusetts
1 shared publication - Carolyn J. Straub
Department of Pharmaceutical Sciences, College of Pharmacy, University of Illinois Chicago, Chicago, Illinois 60612, United States
1 shared publication - David Giacalone
Affiliations Department of Molecular Biology and Microbiology, Tufts University School of Medicine, Boston, Massachusetts, United States of America, Graduate Program in Molecular Microbiology, Graduate School of Biomedical Sciences, Tufts University, Boston, Massachusetts, United States of America
1 shared publication J. Fraser Glickman
Affiliation High-Throughput and Spectroscopy Resource Center, The Rockefeller University, New York, New York, United States of America
1 shared publication- Jimmy S. Patel
Winship Cancer Institute
1 shared publication
Latest Publications
- 28 November 2022
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 66 (1) , 107-121
What We Have Gained from Ibogaine: α3β4 Nicotinic Acetylcholine Receptor Inhibitors as Treatments for Substance Use Disorders
For decades, ibogaine-the main psychoactive alkaloid found in Tabernanthe iboga-has been investigated as a possible treatment for substance use disorders (SUDs) due to its purported ability to interrupt the addictive properties of multiple drugs of abuse. Of the numerous pharmacological actions of ibogaine and its derivatives, the inhibition of alpha 3 beta 4 nicotinic acetylcholine receptors (nAChRs), represents a probable mechanism of action for their apparent anti addictive activity. In this Perspective, we examine several classes of compounds that have been discovered and developed to target alpha 3 beta 4 nAChRs. Specifically, by focusing on compounds that have proven efficacious in pre-clinical models of drug abuse and have been evaluated clinically, we highlight the promising potential of the alpha 3 beta 4 nAChRs as viable targets to treat a wide array of SUDs. Additionally, we discuss the challenges faced by the existing classes of alpha 3 beta 4 nAChR ligands that must be overcome to develop them into therapeutic treatments.
- 28 November 2022
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 66 (1) , 107-121
What We Have Gained from Ibogaine: α3β4 Nicotinic Acetylcholine Receptor Inhibitors as Treatments for Substance Use Disorders
For decades, ibogaine-the main psychoactive alkaloid found in Tabernanthe iboga-has been investigated as a possible treatment for substance use disorders (SUDs) due to its purported ability to interrupt the addictive properties of multiple drugs of abuse. Of the numerous pharmacological actions of ibogaine and its derivatives, the inhibition of alpha 3 beta 4 nicotinic acetylcholine receptors (nAChRs), represents a probable mechanism of action for their apparent anti addictive activity. In this Perspective, we examine several classes of compounds that have been discovered and developed to target alpha 3 beta 4 nAChRs. Specifically, by focusing on compounds that have proven efficacious in pre-clinical models of drug abuse and have been evaluated clinically, we highlight the promising potential of the alpha 3 beta 4 nAChRs as viable targets to treat a wide array of SUDs. Additionally, we discuss the challenges faced by the existing classes of alpha 3 beta 4 nAChR ligands that must be overcome to develop them into therapeutic treatments.
- Open Access
- 28 July 2021
- Published by Public Library of Science (PLoS) in PLOS Biology
- Vol. 19 (7) , e3001355
Targeting Mycobacterium tuberculosis response to environmental cues for the development of effective antitubercular drugs
Sensing and response to environmental cues, such as pH and chloride (Cl−), is critical in enabling Mycobacterium tuberculosis (Mtb) colonization of its host. Utilizing a fluorescent reporter Mtb strain in a chemical screen, we have identified compounds that dysregulate Mtb response to high Cl− levels, with a subset of the hits also inhibiting Mtb growth in host macrophages. Structure–activity relationship studies on the hit compound “C6,” or 2-(4-((2-(ethylthio)pyrimidin-5-yl)methyl)piperazin-1-yl)benzo[d]oxazole, demonstrated a correlation between compound perturbation of Mtb Cl− response and inhibition of bacterial growth in macrophages. C6 accumulated in both bacterial and host cells, and inhibited Mtb growth in cholesterol media, but not in rich media. Subsequent examination of the Cl− response of Mtb revealed an intriguing link with bacterial growth in cholesterol, with increased transcription of several Cl−-responsive genes in the simultaneous presence of cholesterol and high external Cl− concentration, versus transcript levels observed during exposure to high external Cl− concentration alone. Strikingly, oral administration of C6 was able to inhibit Mtb growth in vivo in a C3HeB/FeJ murine infection model. Our work illustrates how Mtb response to environmental cues can intersect with its metabolism and be exploited in antitubercular drug discovery.
- 28 July 2021
- Published by Public Library of Science (PLoS) in PLOS Biology
- Vol. 19 (7) , e3001355
Open AccessTargeting Mycobacterium tuberculosis response to environmental cues for the development of effective antitubercular drugs
Sensing and response to environmental cues, such as pH and chloride (Cl−), is critical in enabling Mycobacterium tuberculosis (Mtb) colonization of its host. Utilizing a fluorescent reporter Mtb strain in a chemical screen, we have identified compounds that dysregulate Mtb response to high Cl− levels, with a subset of the hits also inhibiting Mtb growth in host macrophages. Structure–activity relationship studies on the hit compound “C6,” or 2-(4-((2-(ethylthio)pyrimidin-5-yl)methyl)piperazin-1-yl)benzo[d]oxazole, demonstrated a correlation between compound perturbation of Mtb Cl− response and inhibition of bacterial growth in macrophages. C6 accumulated in both bacterial and host cells, and inhibited Mtb growth in cholesterol media, but not in rich media. Subsequent examination of the Cl− response of Mtb revealed an intriguing link with bacterial growth in cholesterol, with increased transcription of several Cl−-responsive genes in the simultaneous presence of cholesterol and high external Cl− concentration, versus transcript levels observed during exposure to high external Cl− concentration alone. Strikingly, oral administration of C6 was able to inhibit Mtb growth in vivo in a C3HeB/FeJ murine infection model. Our work illustrates how Mtb response to environmental cues can intersect with its metabolism and be exploited in antitubercular drug discovery.